Emeren Group Announces Completion of Merger

Emeren Group Ltd (“Emeren” or the “Company”) (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced the completion of the merger contemplated by the previously announced agreement and plan of merger dated June 18, 2025,as amended by an amendment agreement dated September2, 2025 (the “Merger Agreement”), among the Company, Shurya […]

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

(NASDAQ:GLSI), STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01.

Merriam-Webster Announces “Slop” as the 2025 Word of the Year

Springfield, MA, Dec. 15, 2025 (GLOBE NEWSWIRE) — Today Merriam-Webster announced the 2025 Word of the Year: slop. Slop is defined as “digital content of low quality that is produced usually in quantity by means of artificial intelligence.” Throughout 2025, lookup volume of slop on Merriam-Webster.com reflected a flood of slop into everyday life, including

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN(TM) 3.9% Rapamycin Anhydrous Gel (QTORIN(TM) rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

(NASDAQ:PVLA), 73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Overall cVM-IGA at Week 12 Achieved statistical significance on multiple pre-specified clinician-reported and patient-reported efficacy

Azimut and SOQUEM to Participate in LiFT Power’s Consolidation of the Galinee-Adina Lithium District in the James Bay Region of Quebec

(TSX-V:AZM),(OTC US:AZMTF),(Other OTC:AZMTF),(TSX-V:LIFT),(OTCQX:LIFFF), LONGUEUIL, Quebec, Dec. 15, 2025 (GLOBE NEWSWIRE) — Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to announce the signing, together with SOQUEM Inc. (“SOQUEM”), of a non-binding letter of intent (“LOI”) to restructure their 50/50 joint venture on the Galinee Property (the “Property”) in the Eeyou

ArrowMark Financial Corp. Announces Q3 Results and Special Distribution of $0.10 and Regular Cash Distribution of $0.45 per Share for the Fourth Quarter 2025

(NasdaqGM:BANX), DENVER, Dec. 15, 2025 (GLOBE NEWSWIRE) — ArrowMark Financial Corp. (Nasdaq: BANX) (“ArrowMark Financial” or the “Company”), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a special cash distribution of $0.10 per share generated from excess income, and a regular quarterly cash distribution of $0.45 per

Hooker Furnishings Completes Sale of Pulaski Furniture and Samuel Lawrence Furniture for Approximately $6.1 Million

(NASDAQ:HOFT), MARTINSVILLE, Va., Dec. 15, 2025 (GLOBE NEWSWIRE) — Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (“Hooker” or the “Company”), a global leader in home furnishings, today announced it has completed the sale of the Pulaski Furniture and Samuel Lawrence Furniture casegoods brands to Magnussen Home Furnishings, Inc. for approximately $6.1 million, subject to certain final customary

KBR Awarded Green Ammonia Project by IGNIS in Spain

(NYSE:KBR), HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) announced today that it has been awarded a technology and engineering contract by IGNIS for a new green ammonia facility in A Coruna, Spain. Under the terms of the contract, KBR will provide proprietary engineering design and pre-FEED engineering services to IGNIS for a

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 GlobeNewswire December 15, 2025 STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to

Scroll to Top